Sepsis caused by New Delhi metallo-β-lactamase (blaNDM-1) and qnrD-producing Morganella morganii, treated successfully with fosfomycin and meropenem: case report and literature review  by Seija, Verónica et al.
International Journal of Infectious Diseases 30 (2015) 20–26Sepsis caused by New Delhi metallo-b-lactamase (blaNDM-1) and
qnrD-producing Morganella morganii, treated successfully with
fosfomycin and meropenem: case report and literature review
Vero´nica Seija a,1, Julio Ce´sar Medina Presentado b,1, Ine´s Bado c, Romina Papa Ezdra c,
Noelia Batista a, Claudia Gutierrez a, Mariana Guirado b, Macarena Vidal b, Marcelo Nin d,
Rafael Vignoli c,*
aDepartamento de Laboratorio Clı´nico, A´rea Microbiologı´a, Hospital de Clı´nicas, Facultad de Medicina, Universidad de la Repu´blica, Montevideo, Uruguay
bCa´tedra de Enfermedades Infecciosas, Instituto de Higiene, Facultad de Medicina, Universidad de la Repu´blica, Montevideo, Uruguay
cDepartamento de Bacteriologı´a y Virologı´a, Instituto de Higiene, Facultad de Medicina, Universidad de la Repu´blica, Alfredo Navarro 3051, CP
11600 Montevideo, Uruguay
dCentro de Nefrologı´a Hospital de Clı´nicas, Facultad de Medicina, Universidad de la Repu´blica, Montevideo, Uruguay
A R T I C L E I N F O
Article history:
Received 27 February 2014
Received in revised form 17 September 2014
Accepted 18 September 2014
Corresponding Editor: Eskild Petersen,
Aarhus, Denmark
Keywords:
NDM-1
Morganella morganii
Sepsis
Meropenem
Fosfomycin
S U M M A R Y
Objectives: The objective of this study was to describe the microbiological characteristics of an
extensively drug-resistant (XDR) isolate of Morganella morganii obtained from a patient with sepsis of
urinary origin and to describe the patient’s clinical characteristics. We further aimed to perform a
literature review of the situation in Latin America regarding Gram-negative bacillus (GNB) carriers of
New Delhi metallo-b-lactamase (NDM-1) and qnr genes and current reports on the treatment of
infections caused by XDR enterobacteria, with particular attention to colistin-resistant isolates.
Methods: The patient’s clinical data were obtained from his medical history. Microbiological
identiﬁcation and susceptibility testing were done using the VITEK 2 Compact System. Resistance
genes were detected by PCR and sequencing.
Results: Blood and urine cultures grew an M. morganii isolate (Mm4232) harboring NDM-1 and qnrD1.
The patient was treated successfully with fosfomycin and double doses of meropenem. There are no
previous reports of the use of fosfomycin and meropenem to treat infections by XDR enterobacteria
harboring NDM-1 carbapenemase.
Conclusions: This is the ﬁrst report of qnrD1 in South America. We consider that this report could be
helpful to physicians implementing treatments for infections caused by XDR GNB, including colistin–
carbapenem-resistant GNB.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Morganella morganii is a Gram-negative rod belonging to the
Enterobacteriaceae family. It is ubiquitous in the environment and
can cause nosocomial outbreaks and serious infections in
immunocompromised patients.1
This species produces an inducible, chromosomally-encoded
AmpC b-lactamase which is responsible for its natural resis-* Corresponding author. Tel./Fax: +598 2487 57 95.
E-mail address: rvignoli@higiene.edu.uy (R. Vignoli).
1 Both authors contributed equally to the experimental work and the elaboration
of this report.
http://dx.doi.org/10.1016/j.ijid.2014.09.010
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).tance to aminopenicillins, amoxicillin–clavulanate, and ﬁrst-
and second-generation cephalosporins. M. morganii mutants
with derepressed expression of this AmpC are resistant to third-
generation cephalosporins, monobactams, and cephamycin.2
Additionally M. morganii is naturally resistant to tetracyclines,
tigecycline, polymyxins, and nitrofurantoin.3 In this context,
the acquisition of additional resistance genes encoding carba-
penemases and/or transferable plasmid-mediated quinolone
resistance mechanisms signiﬁcantly reduces the therapeutic
options.
The emergence of carbapenemases in Enterobacteriaceae is a
growing concern, with a high impact on patient health worldwide.4
Carbapenemases are enzymes that are able to hydrolyze nearly allciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
V. Seija et al. / International Journal of Infectious Diseases 30 (2015) 20–26 21b-lactam antibiotics, including carbapenems. These enzymes can
belong to molecular classes A, B, or D: KPC (Klebsiella pneumoniae
carbapenemase), NDM (New Delhi metallo-b-lactamase) or VIM
(Verona integron-encoded metallo-b-lactamase), and OXA-48
(oxacillinase) are the most representative exponents of each
group, respectively.5
NDM-1 was ﬁrst described in 2008 in Sweden from a patient
who had previously been hospitalized in New Delhi, India.6 Rapid
worldwide dissemination followed.5,7,8
Several plasmid-mediated quinolone resistance (PMQR) mecha-
nisms have been discovered during the past decade, including
Qnr proteins, QepA transporters, and the acetyltransferase AAC(60)-
Ib-cr.9 Different lineages of Qnr proteins have been described (QnrA,
QnrB, QnrS, and more recently, QnrC and QnrD), with several allelic
variants known for some of them. The qnrD gene was ﬁrst described
in 2009 in a human clinical isolate of Salmonella enterica serovar
Kentucky and three Salmonella enterica serovar Bovismorbiﬁcans
isolates from China.10 In 2011, Mazzariol et al. described the presence
of qnrD in isolates of Proteus mirabilis and M. morganii, suggesting
that this gene might be closely linked to the Proteeae tribe.11
In this work we present a case report of sepsis caused by an
extensively drug-resistant (XDR; according to the deﬁnition
proposed by Magiorakos et al.12) M. morganii isolate (Mm4232)
co-harboring NDM-1 and qnrD1, which was treated successfully
with fosfomycin and double doses of meropenem. In addition, we
reviewed the literature on plasmid-mediated quinolone resistance
and NDM-1 in Latin America, and the experience of therapeutic
options for the treatment of invasive infections caused by XDR
microorganisms.
2. Methods
2.1. Patients
The patient’s clinical data were collected retrospectively by
review of the medical records.
2.2. Bacterial identiﬁcation and susceptibility assays
Bacterial identiﬁcation and antibiotic susceptibility were
determined using the VITEK 2 Compact System (bioMe´rieux,
Durham, NC, USA) and Etest, in accordance with the manufac-
turer’s recommendations. Antibiotic susceptibility to fosfomycin
was determined using Etest strips containing this agent and 25 mg/
l glucose-6-phosphate, as per the manufacturer’s recommenda-
tions. Susceptibility was interpreted according to the European
Committee on Antimicrobial Susceptibility Testing (EUCAST)
breakpoints (http://www.eucast.org).
2.3. Metallo-b-lactamase screening and carbapenemase screening
The imipenem–EDTA/SMA (ethylenediaminetetraacetic acid
372 mg/sodium mercaptoacetic acid 900 mg) double disk13 and
Rosco Diagnostica Neo-Sensitabs KPC and MBL conﬁrmation kit
were used to detect carbapenemases. Testing was performed in
accordance with the manufacturers’ instructions.
2.4. Detection of antibiotic resistance genes
The presence of blaNDM and additional b-lactamases such as the
blaCTX-M, blaSHV, blaTEM, blaPER-2, blaOXA-1, and blaOXA-2 subgroups,
was determined using PCR and sequencing, as described previous-
ly.13–16 The presence of other carbapenemases such as blaIMP,
blaSIM, blaSPM, blaGIM, blaVIM, blaKPC, and blaOXA-48 was sought by
PCR using speciﬁc primers (see Supplementary Material,
Table S1).In order to identify additional genes responsible for the
resistance proﬁle, and associations with mobile genetic elements,
we studied the following by PCR and sequencing: (1) the presence
of plasmid-mediated quinolone resistance genes (qnrA, qnrB, qnrC,
qnrD, qnrS, qepA, aac(60)Ib-cr), (2) the presence of class 1 and
2 integrons, and (3) the presence of insertion sequences ISEcp1,
IS26, IS903, and ISCR1.17
2.5. Conjugation assays
Conjugation assays were carried out using rifampin-resistant
Escherichia coli J53-2 (rifampin-resistant, non-motile, and orni-
thine-negative) as recipient, as described previously.18 Salmonella
enterica serovar Typhimurium harboring conjugative plasmid
pSTM709 (accession number HG428759) was used as the
conjugation positive control.19
3. Results
3.1. Case report
A 24-year-old man with a history of hypertension and end-
stage renal disease secondary to glomerulonephritis had been on
hemodialysis for 7 years. Eight months before presenting to the
hospital he underwent a renal transplant, which was complicated
by a urinary leak (requiring insertion of a double J ureteral stent)
and a urinary tract infection caused by Enterobacter cloacae; this
infection was treated with piperacillin–tazobactam for 21 days. He
had been taking the following medications since then: prednisone
(10 mg/day), tacrolimus (4 mg/day), and mycophenolate mofetil
(1 g/day).
On admission to the emergency department, the patient
presented fever, dysuria, and a decreased urine output. Initial
vital signs were as follows: temperature 38.2 8C, normal blood
pressure, heart rate 100 beats/min, and arterial oxygen saturation
of 96% when breathing air. The patient appeared ill and jaundiced;
his abdomen was tender without pain. The rest of the examination
was normal.
Urinalysis by dipstick test showed leukocyte esterase, nitrite,
protein, and hemoglobin, and urine microscopic examination
revealed 15 leukocytes and 7 erythrocytes per high-power ﬁeld. In
addition, laboratory studies on admission showed elements of
multiple organ dysfunction such as pancytopenia, renal and
hepatic failure, and high values of biomarkers such as procalcitonin
(38 ng/ml; according to the manufacturer, procalcitonin values
10 ng/ml can be interpreted as indicating a high likelihood of
severe sepsis or septic shock) and C-reactive protein (CRP, 129 mg/
l; reference value CRP <3 mg/l). The changes in laboratory results
over time are shown in Table 1; results from the medical
examination done 1 month before admission are included.
Chest radiography was normal. Computed tomography (CT) of
the thorax, abdomen, and pelvis showed no alterations except for
the presence of the ureteral stent.
In this immunocompromised patient with a diagnosis of sepsis,
treatment with meropenem (1 g every 8 h) was initiated and doses
of immunosuppressive agents were reduced: tacrolimus 2 mg/day,
mycophenolate mofetil 500 mg/day, and prednisone 5 mg/day.
Urine and blood culture results were received after 48 h; both
samples grew an M. morganii isolate (named in our laboratory as
Mm4232), which displayed susceptibility only to fosfomycin.
Testing of susceptibility to colistin and tigecycline was not done.
Additionally, isolate Mm4232 was resistant to cefepime (FEP),
ceftazidime (CAZ), cefotaxime (CTX), piperacillin–tazobactam
(PTZ), imipenem (IMP), meropenem (MEM), ertapenem (ERT),
ciproﬂoxacin (CIP), gentamicin (CN), amikacin (AK), and trimetho-
prim–sulfamethoxazole (SXT) (see results below).
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sepsis with bacteremia and the potential risk of the emergence of
resistance during fosfomycin monotherapy, we decided to use
combination therapy based on meropenem, administered by
extended infusion (lasting 3 h) at a dose of 2 g every 8 h, along
with fosfomycin, 4 g every 8 h with daily natremia control. During
hospitalization, the ureteral stent was removed without complica-
tions. After 10 days of fosfomycin and 14 days of meropenem
treatment, the patient was discharged having made excellent
clinical progress and with full renal function recovery (Table 1). A
follow-up urine culture on day 14 was negative.
3.2. Susceptibility testing
M. morganii strain Mm4232 was only susceptible to fosfomycin
(minimum inhibitory concentration (MIC) 32 mg/ml). Mm4232
was resistant to cefepime (4 mg/l), ceftazidime (64 mg/l),
cefotaxime (64 mg/l), piperacillin–tazobactam (128 mg/l),
ertapenem (4 mg/l), meropenem (4 mg/l), imipenem (16 mg/l),
ciproﬂoxacin (4 mg/l), gentamicin (16 mg/l), amikacin (32 mg/
l), and trimethoprim–sulfamethoxazole (320 mg/l).
3.3. Carbapenemase screening
The imipenem–EDTA double disk showed an improvement in
the inhibition zone in the area between the carbapenems and
the inhibitor-containing disk. The Rosco kit displayed a 7 mm
difference between the meropenem disk (21 mm) and meropenem
+ dipicolinic acid disk (28 mm). Both results were interpreted as
positive for the detection of metallo-b-lactamase.
3.4. Antibiotic resistance genes
Mm4232 was positive for blaNDM-1 and qnrD1, but was negative
for other b-lactamase and plasmid-mediated quinolone resistance
genes. In addition, this isolate was IS26-positive but negative for
other insertion sequences and integrons. PCRs aimed at connecting
IS26 with blaNDM-1 and/or qnrD1 were negative, suggesting that
this IS was not surrounding resistance genes.
3.5. Conjugation assays
Results of conjugation assays were negative using M. morganii
strain Mm4232, but positive using S. enterica serovar Typhimurium
strain STM709. These ﬁndings suggest that both blaNDM-1 and
qnrD1 were codiﬁed in non-conjugative elements. More studies areTable 1
Main laboratory results
Control (1 month before admission)
Urea, mg/dl 0.57 
Creatinine, mg/dl 1.44 
Hemoglobin, g 13.1 
WBC count, 109/l 5.800 
Neutrophils, 109/l 3.300 
Total lymphocytes, 109/l 1.330 
Platelet count, 109/l 159 
Total bilirubin, mg/dl 0.46 
Direct bilirubin, mg/dl 0.23 
AST, U/l 39 
ALT, U/l 112 
Procalcitonin, ng/ml ND 
Na, mEq/ml 140 
CRP, mg/l ND 
Tacrolimus trough concentration, ng/ml 14 
WBC, white blood cell; AST, aspartate aminotransferase; ALT, alanine aminotransferaserequired to determine if these genes are located in non-conjugative
plasmids or the bacterial chromosome.
4. Discussion
Reports on NDM-producing isolates in Latin America and
Central America are relatively few and have been published only
from Mexico,20 Jamaica,21 Guatemala,22 Honduras,23 Colombia,24
Paraguay,25 and Brazil.26–28 A Pan American Health Organization
(PAHO) epidemiological update has also given accounts of the
presence of NDM-1 in Costa Rica, Nicaragua, Argentina, and
Uruguay.29 The main characteristics of isolates and clinical cases
reported in Latin America, including the one presented in this
work, are shown in Table 2.
So far, most of the reported cases have resulted from outbreaks
of nosocomial infections (12/17) and have been associated with a
low mortality attributable to the infection itself. The treatment
was recorded in 11 cases and combinations of antibiotics were
used in nine of them; a carbapenem was used in eight of these
combinations. Other than the case presented in this paper,
fosfomycin susceptibility has only been reported in a work from
Guatemala; this has not been used as a therapeutic option at any
other time.
In contrast, infections and/or colonization of humans by GNB
carrying qnr genes in Latin America has been better described. In
brief, there are three mechanisms of plasmid-mediated quinolone
resistance (PMQR): (1) protection by masking the target qnr genes,
and (2) modiﬁcation of the antibiotic enzyme Aac(60)-Ib-cr and
efﬂux pumps OqxAB and QepA. The qnr genes constitute the ﬁrst
mechanism of transferable quinolone resistance described; reports
date back to the year 1998.30 The Qnr protein binds to gyrase,
causing the quinolones to recognize the less efﬁcient target enzyme.
Variants of this gene have arisen over time. qnrA came ﬁrst, followed
by the qnrB, qnrS, qnrC, qnrD, and qnrVC gene families. Currently, the
following variants have been described: qnrA1–qnrA7, qnrB1–
qnrB74, a variant of qnrC, qnrD1–qnrD2, qnrS1–qnrS9, and
qnrVC1–qnrVC6 (http://www.lahey.org/qnrStudies/).
A variety of qnr genes have been described in Latin America. In
Brazil, the ﬁrst report on qnr genes involved E. coli, with qnrA1
associated with blaFOX-5;
31 qnrB2, qnrB8, qnrB19, qnrS1, and
qnrVC32–35 were then detected. In Argentina, qnrB1, qnrB2, qnrB4,
qnrB6, qnrB10, qnrB19, and qnrS have been found.36–38 In Bolivia,
qnrS and qnrB;39,40 in Peru, qnrB19 and qnrS;40,41 in Uruguay,
qnrA1, qnrB1, qnrB4, qnrB8-like, qnrB13, and qnrB17;14,42 and in
Venezuela qnrB19,43 have been reported. The qnr genes have been
described in a variety of microorganisms isolated either from Admission Day 2 Day 8 Day 13 Day 15
0.69 0.51 0.39 0.52 0.52
2.35 1.74 1.32 1.23 1.23
14 12.3 13.2 13 12
0.740 4.950 4.740 5.200 4.090
0.580 3.217 2.700 3.300 2.800
0.130 0.840 1.410 1.180 1.000
74 83 160 160 186
1.64 0.75 ND 0.18 ND
0.98 0.45 ND 0.12 ND
132 50 ND 40 ND
123 122 ND 121 ND
38 31.4 2.29 0.13 ND
128 131 134 132 133
129 ND ND 18 ND
11.4 ND 9.4 ND 8.6
; CRP, C-reactive protein; ND, not determined.
Table 2
Main features of clinical reports of human infections due to New Delhi metallo-b-lactamase-producing Gram-negative bacteria in Latin America
Country Year Microorga-
nisma
Sex/age
(years)
Site of
infection
Underlying
condition
Antibiotic
resistance
Antibiotic
susceptibility
Therapy Microbiological
outcome
and (observations)
Outbreak
(yes/no)
Ref.
Uruguay 2013 M. morganii M/24 Urosepsis Renal transplant; on
immunosuppressive
therapy with prednisone,
tacrolimus, and
mycophenolate
TGC, CRB, PTZ, CIP,
CN, AK, SXT, and
natural resistance
to TIG, COL and NT
FOS FOS/MEM Success No This
work
Guatemala 2011 K. pneumoniae ND/1 Nosocomial
pneumonia/
septic shock
ND TGC, CRB, PTZ, CIP,
CHL, NT
CN, AK, NAL, TIG, FOS, COL PTZ/AK Success Yes 22
Guatemala 2011 K. pneumoniae ND/ND Tracheal
secretion
Head and neck trauma from
gunﬁre
TGC, CRB, PTZ, CIP,
CHL, NT
CN, AK, NAL, TIG, FOS, COL ND Death (non-
infectious-related
cause)
Yes 22
Colombia 2011 K. pneumoniae F/23 days BSI Preterm, placenta abruptio,
severe perinatal asphyxia,
enterocolitis
TGC, CRB, AK ATM, CIP, TET, TGC, COL MEM/RIF Success Yes 24
Colombia 2011 K. pneumoniae M/9 days NEC Preterm, chorioamnionitis TGC, CRB, AK ATM, CIP, TET, TGC, COL IPM/CIP Success Yes 24
Colombia 2011 K. pneumoniae M/90 days BSI Meconium aspiration
syndrome, severe perinatal
asphyxia, hypoxic–
ischemic encephalopathy
TGC, CRB, AK ATM, CIP, TET, TGC, COL IPM/CIP Success Yes 24
Colombia 2011 K. pneumoniae M/10 days BSI Preterm, toxemic mother,
severe perinatal asphyxia,
pneumonia in utero
TGC, CRB, AK ATM, CIP, TET, TGC, COL IPM/CIP Death (non-
infectious-related
cause)
Yes 24
Colombia 2012 K. pneumoniae F/1 BSI Pneumonia in utero with
spontaneous
pneumothorax, closed
thoracostomy (3 days)
TGC, CRB, AK ATM, CIP, TET, TGC, COL IPM/CIP Success Yes 24
Colombia 2012 K. pneumoniae F/13 Fulminant
NEC
Preterm, chorioamnionitis,
pneumonia in utero
TGC, CRB, AK ATM, CIP, TET, TGC, COL NT Death Yes 24
Mexico 2012 P. rettgeri M/22 UTI ND TGC, CRB, CIP, COL,
CN
TIG ND Death (non-
infectious-related
cause)
Yes 20
Mexico 2012 P. rettgeri M/16 UTI ND TGC, CRB, CIP, COL,
CN
TIG ND Death (non-
infectious-related
cause)
Yes 20
Mexico 2012 P. rettgeri F/50 UTI ND TGC, CRB, CIP, COL CN, TIG ND Success Yes 20
Mexico 2012 P. rettgeri F/53 UTI ND TGC, CRB, CIP, COL, CN, TIG ND Success Yes 20
Honduras 2012 A. baumannii M/76 IAI Peritoneal dialysis TGC, CRB, CIP, AK,
CN, SXT
COL, TIG TIG Success No 23
Brazil 2013 P. rettgeri ND/ND Diabetic foot
infection
Diabetic peripheral
vascular disease
TGC, IMP, CN, and
natural resistance
to TIG, COL, and NT
MEM, ERT, AK AMC Toe amputation
was required
No 26
Paraguay 2012 A. pittii ND/7 CSF ND TGC, CRB, PTZ CN, AK, NAL, CIP, COL, TIG SXT, CIP, AK Death (non-
infectious-related
cause)
No 25
Paraguay 2012 A. pittii ND/2 Sepsis Acute lymphocytic
leukemia
TGC, CRB, PTZ CN, AK, NAL, CIP, COL, TIG MEM, AK Success No 25
AK, amikacin; AMC, Amoxicillin-Clavulanic acid; ATM, Aztreonam; BSI, blood stream infection; CHL, chloramphenicol; CIP, ciproﬂoxacin; CN, gentamicin; COL, colistin; CRB, carbapenems; CSF, cerebrospinal ﬂuid; ERT, ertapenem; F,
female; FOS, fosfomycin; IAI, Intra-abdominal Infection; IPM, imipenem; M, male; MEM, meropenem; NAL, nalidixic acid; ND, not determined; NEC, necrotizing enterocolitis; NT, nitrofurantoin; PTZ, piperacillin–tazobactam; RIF,
rifampin; SXT, trimethoprim–sulfamethoxazole; TET, tetracycline; TGC, third-generation cephalosporins including ceftazidime and cefotaxime; TIG, tigecycline; UTI, urinary tract infection.
a Morganella morganii; Klebsiella pneumoniae; Providencia rettgeri; Acinetobacter baumannii; Acinetobacter pittii.
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infections.14,38,40,42
Meanwhile, the association of NDM and PMQR has been
reported in Guatemala, Colombia, and Brazil.22,24,27 In Guatemala,
two K. pneumoniae ST17 isolates producing NDM-1, aac(60)Ib-cr,
and qnrB1 with the presence of two extended-spectrum
b-lactamases (ESBL), CTX-M-15 and SHV-12, have been
reported.22 In Colombia a K. pneumoniae isolate (ST1043) carrying
qnrA1, associated with ESBL CTX-M-15, has been reported.24
Finally, an Enterobacter hormaechei strain carrying NDM-1 in
conjunction with qnrB4 and CTX-M-15 has been described in
Brazil.27
Most clinical bacteria reported with NDM-1 remain susceptible
in vitro only to colistin and to either or both tigecycline and
fosfomycin.44 This was not the case for our isolate.
M. morganii is naturally resistant to tigecycline and to
polymyxins.3 In addition, the Mm4232 isolate was resistant to
all b-lactam antibiotics, including carbapenems and in combina-
tions with inhibitors, aminoglycosides, and trimethoprim–sulfa-
methoxazole. Taking into account this antibiotic resistance proﬁle,
the Mm4232 isolate was considered to be XDR. This extensive
pattern of drug resistance left only fosfomycin as an option for
treatment.
There have been no randomized clinical studies on how
to treat infections caused by carbapenemase-producing
Enterobacteriaceae. Evidence comes from non-randomized studies
with a retrospective design. The majority of studies refer to KPC-
producers, and some to VIM-producers and carbapenem-resistant
isolates. NDM-producers are hardly mentioned.45 The available
evidence suggests that infections caused by carbapenemase-
producers have better outcomes when combination therapy is
used.46,47
Tigecycline in combination with colistin, carbapenem in
combination with colistin, and tigecycline in combination with
gentamicin are the most commonly administered antibiotic
regimens among the published studies and might result in lower
mortality than other antibiotic combinations.48–54 In general,
carbapenems are administered to patients infected with strains for
which the MICs are low (4 mg/l and probably up to 8 mg/l). There
are studies that mention an important increase in survival when a
carbapenem is administered in combination with another drug. It
is important that a high-dose prolonged infusion regimen is
administered to drive the pharmacokinetic/pharmacodynamic
(PK/PD) proﬁle towards acceptable exposures.50,51,55
Fosfomycin represents a potential last-resort treatment option
for infections caused by carbapenemase-producers.47 In vitro
studies have demonstrated fosfomycin synergy in combination
with imipenem and meropenem in 74% and 70% of KPC-producing
K. pneumoniae isolates, respectively.56 Fosfomycin in combination
with colistin, gentamicin, or piperacillin–tazobactam has shown a
promising clinical success rate (100%) in the treatment of serious
infections caused by carbapenem-resistant K. pneumoniae.57
However, the potential emergence of resistance during therapy
has been reported.58
In a recent study, Pontikis et al. described a series of patients
with infections caused by XDR Pseudomonas aeruginosa and K.
pneumoniae, according to the deﬁnition used in our work. These
patients were treated with fosfomycin in combination with various
antibiotics, including meropenem in some cases.59 However, it is
not clear how many cases received the fosfomycin–meropenem
combination, or what the cure rate was for this. None of these
microorganisms were NDM carbapenemase-producers.
In Uruguay, the surveillance of carbapenemase-producing
isolates is done by the Ministry of Public Health (http://
www.msp.gub.uy), but the dissemination of the results is poor.29,60
So far, there have been no reports combining the detection ofdifferent resistance genes and the clinical outcomes of infected
patients. We recently reported the detection and control of the ﬁrst
outbreak in our country caused by KPC-producing K. pneumoniae
ST258.61
In this paper we reported the successful management of an
immunocompromised patient with urosepsis produced by XDR M.
morganii only susceptible to fosfomycin. The patient was treated
with meropenem and fosfomycin and showed a clinical improve-
ment and reduction of acute-phase markers such as procalcitonin
and CRP.
Fosfomycin is rarely used in Latin America and there are very
few reports on its susceptibility.22 Similarly, the use of the
fosfomycin–meropenem combination for XDR strains is poorly
reported and it is not easy to interpret the results of such a
therapeutic combination.59
To our knowledge this is the ﬁrst report of severe sepsis caused
by blaNDM-1-producing XDR M. morganii. In this context we
consider that our report could be helpful to physicians and
provides well-documented information on an alternative treat-
ment for infections caused by XDR GNB, including colistin–
carbapenem-resistant GNB.
To date qnrD1 has not been reported in Latin America and more
studies will be required to evaluate the dissemination of this PMQR
gene in other species of Enterobacteriaceae.
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